Cargando...
Reduced Dose Ibrutinib Due to Financial Toxicity in CLL
Ibrutinib is the only approved novel agent that is available for the treatment of relapsed-refractory and treatment-naive chronic lymphocytic leukemia patients with deletion 17p or TP53 mutation in India. The cost of ibrutinib is still prohibitive for most Indian CLL patients. We report here for the...
Gardado en:
| Publicado en: | Indian J Hematol Blood Transfus |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Springer India
2018
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6439022/ https://ncbi.nlm.nih.gov/pubmed/30988561 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12288-018-1011-4 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|